New ICR Chief's Three-Pronged Attack On Cancer
Paul Workman, the new chief executive of the Institute of Cancer Research in London has pledged to attack the disease’s ability to evolve and evade treatment.
Prof Workman (pictured), who had been interim CEO since July, says he plans to embed the ICR’s recently-established Centre for Evolution and Cancer and innovative research projects in cancer biology and the disease's survival networks in an integrated programme “aimed at overcoming the scourge of treatment resistance”. He speaks about three priorities in drug discovery, the first being “expanding the druggable cancer genome”.
Help employers find you! Check out all the jobs and post your resume.
Prof Workman (pictured), who had been interim CEO since July, says he plans to embed the ICR’s recently-established Centre for Evolution and Cancer and innovative research projects in cancer biology and the disease's survival networks in an integrated programme “aimed at overcoming the scourge of treatment resistance”. He speaks about three priorities in drug discovery, the first being “expanding the druggable cancer genome”.
Help employers find you! Check out all the jobs and post your resume.